Navigation Links
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Date:12/4/2010

Poster III  
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-383

  • Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia

    • Presenter: Gillian Stephens, Ph.D., Portola Pharmaceuticals
    • Poster Session: Pathophysiology of Thrombosis: Poster II
    • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
    • Location: Hall A3/A4 (Orange County Convention Center)
    • Poster Board III-997

    About Portola Pharmaceuticals, Inc.

    Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible direct-acting i.v. and oral P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care antiplatelet and anticoagulant markets.

    Portola's proprietary pipeline programs are focused on the discovery and development of PRT064445, a novel recombinant protein anticoagulant antidote, known as the Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in
    '/>"/>

    SOURCE Portola Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
    2. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
    3. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
    4. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
    5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
    6. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
    7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
    8. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
    9. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
    10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
    11. Onyx Pharmaceuticals Announces December 2010 Investor Events
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ) today ... modality products. This approval allows the company to sell these products ... the world. "Receiving the CE Mark represents the achievement ... Kelvyn H. Cullimore Jr. , president and CEO of Dynatronics. "Over ... China , Japan , ...
    (Date:7/27/2015)... 27, 2015 According to the ... Study (2014-2019) by Type (DNA ISH, RNA ISH), By ... User (Hospitals, Pharma & Biotech Companies, Research Labs, CROs)", ... million 2014 and is estimated to reach $681.0 million ... forecast period, 2014 to 2019. Browse through ...
    (Date:7/27/2015)... CITY, Calif. , July 27, 2015  Cardica, Inc. ... financial results for its fiscal fourth quarter ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call ... 2015, at 4:30 p.m. Eastern Time via phone, please dial ...
    Breaking Medicine Technology:Dynatronics Awarded CE Mark Approval for Its Solaris Products 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
    ... 22, 2010 Delcath Systems, Inc. (Nasdaq: ... the remaining modules of its 505(b)(2) New Drug Application ... Food & Drug Administration (FDA). The Company had previously ... to the FDA in late April 2010. The Company ...
    ... 22, 2010 Edge EHR Corp., EDGE, a ... OS®, is pleased to announce the release of ... offices looking to leverage the awesome power of the ... (Logo:   http://photos.prnewswire.com/prnh/20100310/AQ68604LOGO ) ...
    Cached Medicine Technology:Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System 2Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System 3Edge EHR Corp. Announces edgeDMS for iPad, Native Touch-Based Clinical Charting Software for the Paperless Dental Office. 2
    (Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... The ... 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She is recognized ... over 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for ...
    (Date:7/27/2015)... ... 27, 2015 , ... The heroin epidemic is affecting the Charlotte in North ... 7th. The rate for heroin usage has continued to climb around the country in ... less expensive alternative for those with an addiction to prescription opiate medications. According to ...
    (Date:7/27/2015)... ... July 27, 2015 , ... In a piece published ... side of plastic surgery and explained why people should not shy away from their ... the excesses of the few and celebrate it for the modern wonder that it ...
    (Date:7/27/2015)... ... July 27, 2015 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, just recently performed ... patient is high-end athlete, whose accomplishments include running in 27 triathlons and swimming the ... which was diagnosed as tendinitis. I did an ultrasound and found a partial ...
    (Date:7/27/2015)... ... July 27, 2015 , ... Send Word Now, ... mobile collaboration, announced today the latest software release for its award-winning ... feature enhancements. , This software release gives the widely used online application a ...
    Breaking Medicine News(10 mins):Health News:NAPW Inducts Jane Simmons, Counseling Intern at Omar Bradley Middle School of the Northeast Independent School District , Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2
    ... for out-of-hospital cardiac arrest, an analysis of data indicates their ... in an improved rate of survival, according to a study ... study is being released early online because it will be ... of automated external defibrillators (AEDs) has been proposed as a ...
    ... blood biomarker cardiac troponin T (cTnT), a cardiac-specific protein, using ... heart failure or cardiovascular death in older adults, according to ... of JAMA . The study is being released early ... Association,s annual meeting. "Older adults comprise the majority of ...
    ... be caused by the gradual accumulation in the brain of amyloid-beta ... formed from a protein known as APP, which is found in ... study for the disease does not distinguish between the different ... Journal of Biological Chemistry , show that amyloid beta peptide is ...
    ... (HealthDay News) -- Could cholesterol deposits on or around ... preliminary Danish study suggests that the deposits could point ... and early death. Half of patients with such ... cholesterol levels. The research team therefore believes that buildup ...
    ... Reporter , MONDAY, Nov. 15 (HealthDay News) -- Omega-3 fatty ... a type of irregular heartbeat that can cause stroke, new ... don,t work for most patients with AF [atrial fibrillation]," said ... in the Dec. 1 issue of the Journal of ...
    ... News) -- As children mature, increased synchronization between specific ... and others, a new study suggests. This includes ... University Medical Center researchers used functional MRI to examine ... comprise what,s known as the default-mode network (DMN). ...
    Cached Medicine News:Health News:Use of AEDs in hospitals for cardiac arrest not linked with improved survival 2Health News:Use of AEDs in hospitals for cardiac arrest not linked with improved survival 3Health News:Biomarker may be able to help predict risk of heart failure, cardiovascular death 2Health News:Biomarker may be able to help predict risk of heart failure, cardiovascular death 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:Cholesterol on Eyelids Might Point to Heart Risk 2Health News:Omega-3 Supplements Won't Fight Irregular Heartbeat 2Health News:Omega-3 Supplements Won't Fight Irregular Heartbeat 3Health News:Brain Organizes Itself for Introspection as Children Age: Study 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: